title: [Recovery test or immunoradiometric measurement of anti-thyroglobulin autoantibodies for interpretation of thyroglobulin determination in the follow-up of different thyroid carcinoma].
abstract: The determination of thyroglobulin (Tg) in the follow-up of differentiated thyroid carcinomas (DTC), is routinely used in nuclear medicine, although some problems, like a disturbed recovery-test (RT) or autoantibodies to thyroglobulin (TgAb), are well known. But it is a controversial issue in literature, whether the determination of TgAb should be performed beside or instead of the RT.
  
  
  OBJECTIVE
  The study compares the clinical value of the determination of both TgAb and RT with sensitive assays.
  
  
  METHODS
  356 patients (pts) were investigated. The results were compared to the concentration of Tg in the sera of the pts. 288 pts stayed tumor-free, the remaining 68 pts showed a recurrence (local and/or metastatic) of their DTC. We measured Tg (with RT) using an immunoradiometric assay (Tg-IRMA; SELco Tg; Fa. Medipan Diagnostica GmbH) and TgAb using a direct assay (CentAK anti-Tg; also from Fa. Medipan).
  
  
  RESULTS
  The prevalence of TgAb, and of disturbed RT respectively, in the whole population of DTC-pts was 7.6%, in the subgroup of tumor-free pts 6.6%, and in the remaining pts with tumor-recurrence 11.8%, respectively 2.0%, 1.7% and 2.9%. In a significantly higher percentage of pts with local/metastatic recurrence, both a positive TgAb (p < 0.001) and a disturbed RT (p < 0.05) were found. 7/68 pts with tumor-recurrence but Tg < 1 ng/ml showed positive TgAb, only 2/7 had a disturbed RT. In this group, no patient with Tg > 1 ng/ml demonstrated either positive TgAb or disturbed RT (p < 0.001 and p < 0.05).
  
  
  CONCLUSIONS
  The determination of TgAb in the follow-up of DTC is necessary, because it supports a suspicion to tumor-recurrence in pts with negative Tg. Also the RT is of great value because of a possibly High dose hook-effect.
authors.affiliation: Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden, Deutschland. kzophel@rcs.urz.tu-dresden.de
authors.forename: K
authors.initials: K
authors.lastname: Zöphel
authors.forename: G
authors.initials: G
authors.lastname: Wunderlich
authors.forename: U
authors.initials: U
authors.lastname: Liepach
authors.forename: R
authors.initials: R
authors.lastname: Koch
authors.forename: J
authors.initials: J
authors.lastname: Bredow
authors.forename: W G
authors.initials: WG
authors.lastname: Franke
mesh_terms: D018263:Adenocarcinoma, Follicular / Q000097:blood / Q000276:immunology / Q000473:pathology; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001323:Autoantibodies / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D002291:Carcinoma, Papillary / Q000097:blood / Q000276:immunology / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012008:Recurrence; D015203:Reproducibility of Results; D013954:Thyroglobulin / Q000097:blood / Q000276:immunology*; D013964:Thyroid Neoplasms / Q000097:blood* / Q000276:immunology / Q000473:pathology; D013972:Thyrotropin / Q000097:blood
chemical_list: D001323:Autoantibodies; D015415:Biomarkers; D013972:Thyrotropin; D013954:Thyroglobulin